SCHEMBL31654073

SCHEMBL31654073

COc1ccc2nc(O)c(-c3noc(-c4ccccc4)n3)cc2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.60
▸ MEN1 O00255 5/20 0.60
▸ KDM4E B2RXH2 4/20 0.60
▸ HPGD P15428 3/20 0.60
▸ MAPT P10636 6/20 0.59
▸ ALDH1A1 P00352 5/20 0.59
▸ PTPN7 P35236 2/20 0.59
▸ BLM P54132 2/20 0.59
▸ WRN Q14191 2/20 0.59
▸ PKM P14618 1/20 0.59
▸ CTDSP1 Q9GZU7 1/20 0.59
▸ NR1H4 Q96RI1 2/20 0.56
▸ S1PR1 P21453 1/20 0.56
▸ NPC1 O15118 6/20 0.54
▸ RAB9A P51151 6/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ TP53 P04637 5/20 0.54
▸ TDP1 Q9NUW8 2/20 0.54
▸ NFKB1 P19838 1/20 0.54
▸ NFKB2 Q00653 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13912186 1.00 KMT2A (0.60) KMT2AMEN1KDM4EHPGDMAPT
SCHEMBL31654077 0.88 KMT2A (0.61) KMT2AMEN1KDM4EHPGDMAPT
SCHEMBL13912189 0.88 KMT2A (0.61) KMT2AMEN1KDM4EHPGDMAPT
SCHEMBL12420362 0.74 NPC1 (0.88) KMT2AMEN1KDM4EMAPTALDH1A1
SCHEMBL7291752 0.73 NR1H4 (1.00) KMT2AMEN1KDM4EHPGDMAPT
SCHEMBL6697420 0.73 NR1H4 (1.00) KMT2AMEN1KDM4EHPGDMAPT
SCHEMBL21282219 0.71 RAB9A (0.48) KMT2AMEN1KDM4EHPGDMAPT
SCHEMBL21282179 0.71 NPC1 (0.64) KMT2AMEN1HPGDMAPTALDH1A1
SCHEMBL24212403 0.69 NR1H4 (1.00) KMT2AMEN1KDM4EHPGDMAPT
SCHEMBL21282172 0.68 NPC1 (0.61) MAPTALDH1A1PKMS1PR1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY NEW YORK UNIVERSITY (US) 2025-07-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250213569-A1 METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY DCLRE1B, RNASE1, ADAR KMT2A 4125/4885MEN1 3464/4885KDM4E 4082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback